Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEVPRO-3: mevrometostat + enzalutamide in metastatic castration-sensitive prostate cancer
CTR20253702Phase 3Active
- Sponsor
- Pfizer
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mevrometostat, enzalutamide in prostate cancer (PCa), sponsored by Pfizer. Started Oct 2025; status: active.
02
Drugs
mevrometostatenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20253702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253702.